Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, shared a post by Giampaolo Bianchini, Head of the Translational and Immunotherapy Research Group at the San Raffaele Scientific Institute – Milan, on X, adding the following:

“Results from a randomized phase 3 trial will be presented this Thursday at the ESMO Virtual Plenary – intriguing data for all breast oncologists!!”

Quoting Giampaolo Bianchini’s post:

“Join us at the next ESMO Virtual Plenary session!

• Is there a new PARPi option for HER2-neg gBRCA1/2mut MBC?
• Does a combination of PARPi and antiangiogenic drug (apatinib) improve efficacy?
• Are VEGFRi better than bevacizumab?”

Source: Elisa Agostinetto/X and Giampaolo Bianchini/X